# SMOFlipid to Lessen the Severity of Neonatal Cholestasis

> **NCT02721277** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Florida** · enrollment: 2 (actual)

## Conditions studied

- Cholestasis
- Jaundice, Obstructive

## Interventions

- **DRUG:** SMOFlipid

## Key facts

- **NCT ID:** NCT02721277
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05
- **Primary completion:** 2016-12
- **Final completion:** 2017-02-02
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721277, "SMOFlipid to Lessen the Severity of Neonatal Cholestasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02721277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*